



European Monitoring Centre
for Drugs and Drug Addiction

PROGRAMME

Drug-related infectious diseases DRID annual expert meeting

Tuesday 13 June 2017

16.00 — Registration at EMCDDA

17.00 — Opening of the joint event

18.00 — Cocktail

Wednesday 14 June 2017

09.00 — Joint day with the ECDC hepatitis network

(Separate agenda available.)

17.30 — End of joint meeting

14–16 June 2017
EMCDDA, Lisbon

Drug-related infectious diseases (DRID)

Wednesday 14 June 2017: agenda available separately.	
Thursday 15 June 2017	
09.00	<p>Session 1 — DRID welcome</p> <p>Chairs: Isabelle Giraudon, EMCDDA and Vivian Hope, United Kingdom</p> <p>Objective: The purpose of this session is to open the event, to give an overview of EMCDDA activities and to present briefly the agenda and planned products. Furthermore, the session will provide an opportunity to share updates on country developments.</p> <ul style="list-style-type: none"> • Update on the EMCDDA activities in DRID (KI assessment, workbooks, Rapid Communication, outputs from this meeting; DRID framework and developments) — Isabelle Giraudon, EMCDDA • Most recent data, analyses and feedback from the '2017 DRID national updates' — Eleni Kalamara, EMCDDA • Gaps in PWID estimates: can DRID help — Thomas Seyler, EMCDDA • HIV incidence estimates among PWID from the Latvian PWID cohort study — Anda Kivite, Latvia
10.30	Coffee break
14.00	<p>Session 2 — Threat assessment, outbreaks, clusters and other incidents</p> <p>Chairs: Eleni Kalamara, EMCDDA and Esther Croes, the Netherlands</p> <p>Objective: review recent outbreaks and incidents, developments and local/regional level monitoring.</p> <ul style="list-style-type: none"> • Multi-disciplinary approach to the investigation of an outbreak of acute hepatitis C amongst a hard to reach population of homeless PWID — Lucy Jessop, United Kingdom • HIV outbreak 2017 — role of prison (Alytus prison in particular), responses in place — Ieva Vaitkevičiūtė, Lithuania • New HIV outbreak in injecting drug users: HIV treatment cascade and epidemiological analysis — Carole Devaux, Luxembourg • Hepatitis C in Russian speaking drug users in Paris — Marie Jauffret Roustide, France
12.30	Lunch break
14.00	<p>Session 3 — Responses: reducing DRID-related harm</p> <p>Chairs: Dagmar Hedrich, EMCDDA and Hans Henrik Blystad, Norway</p> <p>Objective: discuss new developments and challenges in the responses to DRID, with a focus on supervised drug consumption facilities (DCRs): implementation, practicalities, potential role in testing and directing to treatment.</p> <ul style="list-style-type: none"> • Update of the situation of DCRs worldwide: results from a survey among the international network of drug consumption rooms — Eberhard Schatz, Correlation Network, Amsterdam • Espace GAIA, first DCR in Paris since October 2016: first results and perspectives — Elisabeth Avril, MD, Executive Director, Association Gaia Paris • Evaluation framework for the DCR in Paris and first results on the social acceptability of the Paris facility — Marie Jauffret Roustide, Sociologist, Research Fellow at the French National Institute of Health and Medical Research • Brief updates: Belgium — feasibility study on drug consumption rooms — Luk Van Baelen, Belgium • Discussion
15.30	Coffee break

16.00	<p>Session 4 — Directions for the development of the DRID indicator</p> <p>Chairs: Isabelle Giraudon, EMCDDA and Elena Alvarez, Spain</p> <p>Objective: to discuss estimation of incidence and developments of bio-behavioural surveillance, and their implications for the DRID indicator. Recent national studies and systems developments will be presented. This will be followed by reflections and discussions about what DRID data collection and analysis should be prioritised and supported in the future.</p> <ul style="list-style-type: none"> • Incidence and prevalence of Hepatitis C in Austria — Study Outcomes and First Steps to Improve the Data — Irene Schmutterer, Austria • Indications for decline in HCV and HIV incidence among people who inject drugs in Athens — Anastasios Fotiou, Greece • Enhancing the bio-behavioural surveillance of hepatitis C among PWID in the UK for the era of direct acting anti-virals and 'Treatment as Prevention' (TasP) — Monica Desai, United Kingdom • RDS study among PWID in Kohtla-Jarve (eastern part of Estonia): risk behaviours among PWID (an update, based on a 2016 study and methodological considerations) — Maris Salekešin, Estonia • Questions and discussion on some directions for DRID further consolidation and development
17.30	End of first day

Friday 16 June 2017

09.00	<p>Session 5 — Substance use among MSM and updates on the hepatitis A outbreaks</p> <p>Chairs: Jane Mounteney, EMCDDA and Irena Klavs, Slovenia</p> <p>Objectives: to share and discuss national updates on substance use among MSM, chemsex issues, as well as the current HAV outbreaks in several countries, and their link with chemsex/substance use.</p> <ul style="list-style-type: none"> • Substance use among MSM. Results of SIALON II study in 13 cities in Europe — Magdalena Rosinska, Poland • HAV European outbreak and links (if any?) with chemsex/drug use <ul style="list-style-type: none"> • Germany — Berlin outbreak — Ruth Zimmermann • Portugal — Domingos Duran • Update of the HAV situation in Cheb region (and more recently in Jihomoravsky Region) — Barbara Janikova, Czech Republic • Discussion
10.20	Coffee break
10.45	<p>Session 6 — Monitoring PWIDs access to hepatitis care — the role of national policies</p> <p>Chairs: Antons Mozalevskis, WHO and Dagmar Hedrich, EMCDDA</p> <p>Objective: To present the results of the 'gap survey' on availability of national policies addressing access of PWID to HCV care, carried out in the context of the EMCDDA project 'Hepatitis resources'.</p> <ul style="list-style-type: none"> • Monitoring national policy landscape addressing access of PWID to HCV care (see also related 'EMCDDA working document') — Stine Nielsen, EMCDDA consultant • Round table and discussion: The role of national policies • Identifying areas of PWID's access to HCV care where good practice examples are needed
11.50	<p>Closing remarks</p> <p>Vivian Hope, United Kingdom and Isabelle Giraudon, EMCDDA</p>
12.00	End of meeting

More information, presentations, supporting documents and updates will be available on <http://www.emcdda.europa.eu/meetings/2017/drid>